Drug intelligence / Profile preview

Trivivac

Development stage: Phase 3
Lead developer: Sevapharma
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

Trivivac is a live attenuated combination vaccine designed for the prophylactic immunization against measles, mumps, and rubella. It contains live attenuated strains of the three viruses—measles virus (Rubivirus), mumps virus (Rubulavirus), and rubella virus—formulated to induce immunity by stimulating an immune response that mimics natural infection without causing disease. The vaccine is primarily indicated for use in healthy infants and children to prevent these infectious diseases. Developed originally by Sevapharma, it has been approved in several countries since at least 2010 for routine immunization programs targeting measles, mumps, and rubella[1][6][8].

Brand names: Trivivac
Other names: Trivivac Sevac

Beyond the preview

Go deeper on Trivivac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trivivac.

Explore the full profile